Thursday, August 22, 2019
Wednesday, August 21, 2019
To find out more about this important event and to register, follow this link
Thursday, August 15, 2019
Maintenance therapy is becoming more standard however and so, four years out, there is nothing in the article to suggest that women like me begin maintenance.
This article by Dr. Oliver Dorigo from Stanford University Medical Center, was found on Survivornet.com. Here's what Dr. Dorigo has to say about Nirapamib:
is also being tested in a clinical trial for use after just the first line of chemotherapy. Doctors refer to PARP inhibitors used at this early stage in the treatment course as the drug being given ‘up-front.’ According to Dr. Dorigo, the trial, called the PRIMA trial, is looking at whether can be used in ovarian cancer patients directly after the first round of chemotherapy following surgery, regardless of whether they have a BRCA mutation. Although the results have not been presented or published yet, Dorigo and other specialists believe that there is hope for the use of this drug in this setting.